Citation Tools
PDFRegular and Young Investigator Award Abstracts
Combination Immunotherapies
841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells